Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

522118

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Education: Publications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the potential merits of bringing forward legislative proposals to prevent the publication of books, papers and other material containing health advice which does not have a sound evidence base; and if he will make a statement.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	38715
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>We have no plans to make such an assessment. The Department’s policies and advice are informed by the best available evidence.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 10:55:51 answering member 4020 label Biography information for George Freeman
tabling member	4433 label Biography information for Thangam Debbonaire

522122

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Audit: ICT
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to review and update NICE guidance to take account of emerging new technologies in electronic auditing.
tabling member constituency	Amber Valley
tabling member printed	Nigel Mills
uin	38786
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>Neither the Department nor the National Institute for Health and Care Excellence has any plans to do so.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:20:26 answering member 4020 label Biography information for George Freeman
tabling member	4136 label Biography information for Nigel Mills

522123

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ehlers-Danlos Syndrome: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many cases of Ehlers-Danios Syndrome have been diagnosed in each of the last five years.
tabling member constituency	Aldridge-Brownhills
tabling member printed	Wendy Morton
uin	38845
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>These data are not held centrally by the Department.</p><p>Ehlers-Danlos Syndrome (EDS) is a complex group of heritable disorders of connective tissue with an estimated prevalence of one in 20,000. As EDS appears in a variety of forms rates of diagnosis can be underestimated.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:21:46 answering member 4020 label Biography information for George Freeman
tabling member	4358 label Biography information for Wendy Morton

522125

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what compliance procedures the Medicines and Healthcare Products Regulatory Agency has to ensure that its pharmacovigilance functions do not conflict with the relationships it builds with private companies when seeking business from such companies.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38832
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>The requirements for the pharmacovigilance functions of the Medicines and Healthcare products Regulatory Agency (MHRA) are set out in European legislation through Directive 2010/84/EU and Regulation (EU) No 1235/2010 and in the Human Medicines Regulations 2012. MHRA is required to carry out independent audits of these pharmacovigilance functions and report to the European Commission every two years. This is in addition to routine reporting to the Commission on Human Medicines.</p><p>The requirements on private companies in the pharmaceutical industry that hold Marketing Authorisations for medicinal products are also set out in the same legislation and the MHRA carry out inspections to ensure these companies are compliant with the requirements. The MHRA has contact with pharmaceutical companies in its day to day business as necessary to fulfil the requirements of its pharmacovigilance functions.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:19:19 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

522126

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38833
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins> <del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p> </p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 10:57:37 question first ministerially corrected 13/06/2016 10:14:27 answering member 4020 label Biography information for George Freeman previous answer version 2228 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

522131

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospitals: Patients
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients were discharged from hospital between 11pm and 6am in each of the last six years.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	38624
answer	answer is ministerial correction date of answer 06/06/2016 answer text <p>The information is not held in the format requested.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 38622 question first answered 06/06/2016 15:11:38 answering member 4020 label Biography information for George Freeman
tabling member	1588 label Biography information for Barbara Keeley

522135

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospitals: Admissions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many readmissions within 28 days of discharge from hospital there were for patients over the age of (a) 65, (b) 80 and (c) 90 in (i) England and (ii) each clinical commissioning group and primary care trust area in each of the last six years.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	38622
answer	answer is ministerial correction date of answer 06/06/2016 answer text <p>The information is not held in the format requested.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 38624 question first answered 06/06/2016 15:11:38 answering member 4020 label Biography information for George Freeman
tabling member	1588 label Biography information for Barbara Keeley

522145

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to reduce the cost to the NHS of postage of appointment notifications to patients.
tabling member constituency	Twickenham
tabling member printed	Dr Tania Mathias
uin	38670
answer	answer is ministerial correction date of answer 06/06/2016 answer text <p>The National Information Board’s strategy document <em>Personalised Health and Care 2020 </em>(published November 2014) set out the aim to support greater uptake of the use of digital systems in health and care to create a National Health Service paper free at the point of care by 2020. This will remove the system’s reliance on paper and will help reduce postal service costs for the NHS.</p><p> </p><p>In the case of appointment letters for patients the new NHS e-referral system, introduced last year, already allows healthcare providers to choose not to send out appointment letters, instead allowing patients to access the information directly from the NHS e-referral system. Patients have an option to print off the details of their appointment if they prefer to have a paper copy of the information. We expect increasing numbers of providers will use this functionality to help contain costs.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 06/06/2016 15:15:58 answering member 4020 label Biography information for George Freeman
tabling member	4404 label Biography information for Dr Tania Mathias

522149

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuroendocrine Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.
tabling member constituency	Newcastle upon Tyne East
tabling member printed	Mr Nicholas Brown
uin	38897
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Number of patients treated in 2011/12<sup>1</sup></p></td><td><p>Number of patients treated in 2012/13<sup>1</sup></p></td><td><p>Number of CDF notifications 2013/14<sup>2</sup></p></td><td><p>Number of CDF notifications 2014/15<sup>2</sup></p></td><td><p>Number of CDF notifications 2015/16 (to Sept)<sup> 2</sup></p></td></tr><tr><td><p>Peptide receptor radionuclide therapy (to include Lutetium-177 or Yttrium-90 octreotide analogues)</p></td><td><p>49</p></td><td><p>117</p></td><td><p>152</p></td><td><p>229</p></td><td><p>116</p></td></tr></tbody></table><p><sup>1 </sup>Source: Strategic Health Authority returns to the Department of Health</p><p><sup>2 </sup>Source: NHS England</p><p> </p><p>Information on the number of peptide receptor radionuclide therapy treatments provided outside of the CDF is not collected.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:23:47 answering member 4020 label Biography information for George Freeman
tabling member	523 label Biography information for Mr Nicholas Brown

522150

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuroendocrine Cancer: Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons the Lutathera drug was removed from the list of drugs available under the Cancer Drugs Fund.
tabling member constituency	Newcastle upon Tyne East
tabling member printed	Mr Nicholas Brown
uin	38894
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>Peptide receptor radionuclide therapy (including Luththera) for the treatment of gastro-entero-pancreatic neuroendocrine tumours was removed from the Cancer Drugs Fund in November 2015 on the grounds that it represented insufficient value for retention within the Fund.</p><p>NHS England’s full decision summary is available at:</p><p><a href="https://www.england.nhs.uk/ourwork/cancer/cdf/cdf-drug-sum/" target="_blank">https://www.england.nhs.uk/ourwork/cancer/cdf/cdf-drug-sum/</a></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:25:38 answering member 4020 label Biography information for George Freeman
tabling member	523 label Biography information for Mr Nicholas Brown